期刊文献+

骨髓增生异常综合征线粒体呼吸链酶复合体的变化 被引量:2

The change of mitochondrial respiratory chain complex in patients with myelodysplastic syndrome
下载PDF
导出
摘要 目的:研究骨髓增生异常综合征(MDS)患者骨髓单个核细胞线粒体呼吸链的功能变化并分析其与MDS的关系。方法:测定26例MDS患者与10例骨髓象正常者的单个核细胞线粒体呼吸链酶复合体Ⅰ、Ⅲ、Ⅳ的活性。结果:MDS患者呼吸链酶复合体Ⅰ、Ⅲ、Ⅳ的活性明显低于对照组(P<0.05);线粒体呼吸链酶复合体Ⅰ、Ⅲ的活性在RAEB-Ⅰ、RAEB-Ⅱ组与RA、RARS组的差异无统计学意义(均P>0.05),而酶复合体Ⅳ的活性在RAEB-Ⅰ、RAEB-Ⅱ组较RA、RARS组高,差异有统计学意义(P<0.05)。结论:线粒体呼吸链酶复合体的活性在MDS患者中降低,可能与MDS的病态造血及无效造血有关。 Objective:To investigate the function of mitochondrial respiratory chain in bone marrow mononuclear eell(BMMNC) of myelodysplastie syndrome(MDS) and its relationship with MDS. Method: Activities of respiratory chain complexes Ⅰ , Ⅱand Ⅳwere examined in BMMNC from 26 patients with MDS and 10 normal controls. Result:Activities of respiratory chain complexes Ⅰ , Ⅱand Ⅳ in BMMNC were significantly lower in MDS patients than that in normal controls( P 〈0.05). According to WHO classification,activities of respiratory chain complexes Ⅰ , Ⅲand Ⅳin BMMNC were significantly lower in MDS RAEB-Ⅰ , RAEB-Ⅱ and RA, RARS than normal controls( P d0.05). Activities of respiratory chain complexes Ⅰ and Ⅲin type RAEB- Ⅰ ,RAEB-Ⅱ and type RA,RARS showed no significance difference( P 〉0.05), but the activities,of respiratory chain complexes Ⅳwas significantly higher in MDS RAEB- Ⅰ , RAEB-Ⅱ than RA, RARS( P 〈0.05). Conclusion: Reduced activities of respiratory chain complexes may be related to dysplastie hematopoiesis and ineffective hematopoiesis.
出处 《临床血液学杂志》 CAS 2008年第1期8-10,共3页 Journal of Clinical Hematology
关键词 骨髓增生异常综合征 线粒体 呼吸链酶复合体 Myelodysplastie syndrome Mitoehondria Respiratory chain complex
  • 相关文献

参考文献8

  • 1SINGH KK, RUSSELL J, SIGALA B, et al. Mitochondrial DNA determines the cellular esponse to cancer therapeutic agents[J]. Oncogene, 1999, 48: 6641-6646.
  • 2胡喜梅,樊志荣,周水阳,韦薇,陆翠,曹云芳.骨髓增生异常综合征MIC异常和临床特点[J].临床血液学杂志,2005,18(6):338-340. 被引量:6
  • 3REDDY P L, SHETTY V T, DUTT D, et al. Increased incidence of mitochondrial cytochrome c-oxidase gene mutations in patients with myelodysplastic syndromes[J]. Br J Haematol, 2002, 116: 564-575.
  • 4SHIN M G, KAJIGAYA S, LEVIN B C, et al. Mitochondrial DNA mutations in patients with myelodysplastic syndromes[J]. Blood, 2003, 101: 3118-- 3125.
  • 5VAN DE LOOSDRECHT AA, BRADA SJ, BLOM NR, et al. Mitochondrial disruption and limited apoptosis of erythroblasts are associated with high risk myelodysplasia. An ultrastructural analysis[J]. Leuk Res, 2001, 25: 385--393.
  • 6WALLACE D C. Mitochondrial DNA in aging and disease[J]. Sci Am, 1997,277:40--47.
  • 7GATTERMANN N, WULFERT M, JUNGE B, et al. IneffectⅣe hematopoiesis linked with a mitochondrial tRNA mutation (G3242A) in a patient with myelodysplastic syndrome[J]. Blood, 2004, 103:1499 -- 1502.
  • 8DANIELSON SR, WONG A, CARELLI V, et al. Cells bearing mutations causing Leber's hereditary optic neuropathy are sensitized to Fas-Induced apoptosis [J]. J Biol Chem, 2002, 277: 5810--5815.

二级参考文献8

共引文献5

同被引文献58

引证文献2

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部